Articles

Miami, FL—With too much red tape regarding genetic (ie, hereditary) testing, not enough people are being identified before they have breast cancer, according to Kevin Hughes, MD, FACS, Co-Director, Avon Comprehensive Breast Evaluation Center, Massachusetts General Hospital, Boston. Read More ›

Pembrolizumab plus Enzalutamide Shows Activity in Metastatic Castration-Resistant Prostate Cancer

By William King

AUA Highlights

TON - August 2020, Vol 13, No 4

Treatment with a combination of pembrolizumab (Keytruda) and enzalutamide (Xtandi) continues to show substantial activity in patients with metastatic castration-resistant prostate cancer (CRPC) who have already been treated with abiraterone (Zytiga), according to results of a recent clinical trial, which were presented during the virtual 2020 American Urological Association Annual Meeting. Read More ›

A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer

By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, MN, RN, AOCN

Interview with the Innovators, Video

Videos

Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, deliberate on results from recent clinical trials showing the improvement in progression-free survival after first-line maintenance therapy with PARP inhibitors in patients with ovarian cancer, regardless of HRD status. The experts consider the impact of these data on providing improved treatment options for these patients. Read More ›

Chemotherapy-Free PARP Inhibitor Combination Improves Outcomes versus Single-Agent PARP Inhibitor in Recurrent Ovarian Cancer

Ovarian Cancer

Web Exclusives

In a phase 2 study of women with recurrent platinum-sensitive ovarian cancer, safety and efficacy end points favored the combination of niraparib and bevacizumab over niraparib monotherapy. Read More ›

Olaparib Extends Survival by >1 Year in Women with Relapsed Ovarian Cancer and BRCA Mutation

Ovarian Cancer

Web Exclusives

New study findings represent a significant advance for women with BRCA-related relapsed ovarian cancer responding to platinum-based chemotherapy. Read More ›

Individualized Starting Dose of Niraparib Is Recommended in First-Line Maintenance Setting in Recurrent Ovarian Cancer

Ovarian Cancer

Web Exclusives

In the PRIMA study, patients with recurrent ovarian cancer receiving maintenance therapy with an individualized dose of niraparib had similar efficacy compared with placebo as patients receiving a fixed dose of niraparib while experiencing half as many thrombocytopenic events. Read More ›

Long-Term Responders to Rucaparib More Likely to Have Deleterious BRCA Mutations

Ovarian Cancer

Web Exclusives

In a pooled analysis of 2 randomized trials of rucaparib for the treatment of patients with recurrent high-grade ovarian cancer, deleterious BRCA mutations were identified in 71% of patients with responses lasting at least 1 year but in only 52% of short-term responders. Read More ›

Finding a Pathogenic Mutation on Genetic Testing Does Not Add to Stress or Anxiety in Women with Newly Diagnosed Ovarian Cancer

Ovarian Cancer

Web Exclusives

In a study of 76 English-speaking women with newly diagnosed ovarian cancer who underwent genetic testing, those found to have a pathogenic mutation did not report increased levels of stress, anxiety, or depression compared with pre-genetic testing. Those testing negative for mutations saw their posttest anxiety levels decline. Read More ›

Changes in HRD “Fingerprints” in Patients with Ovarian Cancer and Their Impact on Clinical Outcomes

By Amina Ahmed, MD; Paula Anastasia, MN, RN, AOCN

Interview with the Innovators, Video

Videos

Amina Ahmed, MD, and Paula Anastasia, RN, MN, AOCN, debate the need for rebiopsy and retesting of molecular biomarkers in patients with HRD-discordant responses. The experts agree that reliability of the HRD “fingerprint” is dependent on the validity of the HRD test used as well as the ability to interpret results from these tests. Read More ›

Potential for Anti-Cancer Agents in the Treatment of COVID-19

AVBCC COVID-19 Webcast Series

Web Exclusives

As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today? Read More ›

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 126 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: